FDA Approves C5 siRNA for AChR Positive Myasthenia

FDA approved cemdisiran, Livsayis, for adults with anti-AChR-positive generalized myasthenia gravis on November 18. The approval adds a quarterly subcutaneous C5-silencing option, with a boxed warning and REMS for meningococcal infection.





